Sacubitril/Valsartan (Entresto) is a powerful combination medication that has transformed the treatment of heart failure with reduced ejection fraction (HFrEF). By combining sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker (ARB), this medication helps the heart work more efficiently, improving both symptoms and survival rates.
Why is Entresto So Effective?
✔ Reduces Heart Failure Symptoms – Less breathlessness, swelling, and fatigue.
✔ Lowers Hospitalization Risk – Keeps patients out of the hospital by preventing heart failure flare-ups.
✔ Prolongs Life – Studies show it reduces the risk of cardiovascular death by 20% compared to traditional ACE inhibitors.
✔ Improves Heart Function – Helps reverse harmful heart remodeling, keeping the heart stronger for longer.
✔ Better Tolerated than ACE Inhibitors – Less risk of cough (which is common with ACE inhibitors like ramipril).
How Does It Work?
🔹 Sacubitril – Neprilysin Inhibitor
✔ Neprilysin is an enzyme that breaks down beneficial natriuretic peptides (ANP, BNP, CNP).
✔ Inhibiting neprilysin increases natriuretic peptides, leading to:
- Vasodilation → Lowers blood pressure
- Natriuresis & Diuresis → Reduces fluid overload
- Inhibition of Fibrosis & Hypertrophy → Improves cardiac remodeling
🔹 Valsartan (ARB – Angiotensin II Blocker)
- Blocks angiotensin II, preventing vasoconstriction, sodium retention, and heart muscle stiffening.
📉 The Result? Lower blood pressure, improved circulation, and a healthier, more efficient heart.
Who Should Take Entresto? (Indications)
✔ Patients with HFrEF (LVEF ≤40%) – Especially those with NYHA Class II-IV symptoms.
✔ People who are still symptomatic despite standard therapy (ACE inhibitors, ARBs, beta-blockers).
✔ Patients who can tolerate an ACE inhibitor or ARB – Entresto is usually started after stopping these medications.
💡 Emerging Uses: It is being studied for heart failure with preserved ejection fraction (HFpEF) and post-heart attack heart failure.
How to Take Entresto (Dosing Guidelines)
💊 Starting Dose:
- If switching from an ACE inhibitor, wait at least 36 hours before starting Entresto (to prevent angioedema).
- If new to heart failure treatment or have low blood pressure, start with:
✔ 24/26 mg (sacubitril/valsartan) twice daily - If previously on an ACE inhibitor/ARB and stable, start with:
✔ 49/51 mg twice daily - If tolerating high-dose ARBs/ACE inhibitors, the doctor may start at:
✔ 97/103 mg twice daily (this is the target dose).
📈 Dose Titration:
- Double the dose every 2-4 weeks as tolerated, aiming for the target dose of 97/103 mg twice daily.
📍 Monitoring During Treatment:
✔ Blood Pressure – Watch for low blood pressure (hypotension).
✔ Kidney Function – Regular eGFR checks (especially in patients with kidney disease).
✔ Potassium Levels – Risk of hyperkalemia (high potassium).
✔ Symptoms of Angioedema – Swelling of lips, face, or throat (seek medical help immediately).
Who Should NOT Take Entresto? (Contraindications)
❌ History of Angioedema – Can be life-threatening.
❌ Currently Taking an ACE Inhibitor – Must wait 36 hours after stopping.
❌ Severe Liver Disease (Child-Pugh C) – Drug metabolism is impaired.
❌ Severe Kidney Disease (eGFR <30 mL/min) – Risk of worsening kidney function.
❌ Pregnant or Breastfeeding – Can harm the baby.
❌ Low Blood Pressure (SBP <100 mmHg) – May worsen hypotension.
Final Takeaway
✔ Entresto is a game changer for heart failure – it helps patients feel better, stay out of the hospital, and live longer.
✔ Starting at the right dose and titrating carefully is key to avoiding side effects.
✔ Close monitoring is essential, especially for blood pressure, kidney function, and potassium levels.
